Fundamental Analysis of RANI THERAPEUTICS HOLDINGS-A(NASDAQ:RANI) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to RANI. RANI was compared to 194 industry peers in the Pharmaceuticals industry. RANI has a bad profitability rating. Also its financial health evaluation is rather negative. RANI has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RANI has reported negative net income.

In the past year RANI has reported a negative cash flow from operations.

RANI had negative earnings in each of the past 5 years.

RANI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -69.95%, RANI is not doing good in the industry: 72.92% of the companies in the same industry are doing better.

The Return On Equity of RANI (-1078.87%) is worse than 85.42% of its industry peers.

		Industry Rank	Sector Rank
ROA	-69.95%
ROE	-1078.87%
ROIC	N/A

ROA(3y)-31.23%

ROA(5y)-46.07%

ROE(3y)-121.5%

ROE(5y)-105.72%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RANI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, RANI has less shares outstanding

RANI has a worse debt/assets ratio than last year.

2.2 Solvency

RANI has an Altman-Z score of -5.12. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.12, RANI is doing worse than 66.15% of the companies in the same industry.

RANI has a Debt/Equity ratio of 6.07. This is a high value indicating a heavy dependency on external financing.

RANI has a Debt to Equity ratio of 6.07. This is amonst the worse of the industry: RANI underperforms 85.94% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	6.07
Debt/FCF	N/A
Altman-Z	-5.12

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.93 indicates that RANI should not have too much problems paying its short term obligations.

RANI has a Current ratio of 1.93. This is in the lower half of the industry: RANI underperforms 62.50% of its industry peers.

A Quick Ratio of 1.93 indicates that RANI should not have too much problems paying its short term obligations.

The Quick ratio of RANI (1.93) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.93
Quick Ratio	1.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.49% over the past year.

EPS 1Y (TTM)14.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%29.73%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

RANI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.16% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y24.84%

EPS Next 2Y10.53%

EPS Next 3Y13.92%

EPS Next 5Y16.16%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.

Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RANI's earnings are expected to grow with 13.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.53%

EPS Next 3Y13.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RANI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (11/18/2024, 8:00:01 PM)

After market: 2.02 -0.03 (-1.46%)

2.05

-0.22 (-9.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap109.90M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-69.95%
ROE	-1078.87%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	6.07
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.93
Quick Ratio	1.93
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)14.49%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y24.84%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

RANI THERAPEUTICS HOLDINGS-A (RANI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens